Immune modulation
Modification of immune responses via T-cell maturation, Toll-like receptors or cytokine profiles. Thymus-derived peptides or synthetic analogs are studied in hepatitis B, sepsis and oncology trials.
Peptides on this topic
3 peptides researched for this topicSynthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature.
- Human trialReduction of anxiety symptoms versus placebo reported in Russian clinical pilot studies
Complex of low-molecular polypeptides extracted from calf thymus. Approved in Russia since the 1970s as an immunomodulator. The exact composition is not standardised like a synthetic single peptide; Western controlled studies are largely absent.
- Human trialChanges in T-cell subpopulations (CD4/CD8) and IL-2 response reported in Russian clinical studies of immunocompromised patients
- Human trialAdjuvant effect in chronic infections (tuberculosis, chronic hepatitis) documented in Russian open-label studies
Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU) for hepatitis B treatment and as an immunomodulator.
- Human RCTImprovement of seroconversion rates in chronic hepatitis B observed in some randomised trials
- Human RCTReduction in 28-day mortality in severe sepsis reported in a Chinese multicentre trial (ETASS)